Bioren's technology provides an efficient, automated, in vitro system to generate and optimize antibodies and antibody fragments through a rational, hypothesis-driven approach. Bioren's patented technology is based on synthetic oligonucleotide chemistry to create defined antibody mutations. Hypotheses regarding the impact of a specific amino acid's side-chain chemistry within the antigen binding pocket can then be explored in a systematic manner. Bioren's Look Through MutagenesisT (LTMT) and Walk Through MutagenesisT (WTMT) technologies enable targeted amino acids to be inserted in each individual position and in all possible combination of multiple positions in an antibody's CDR to create a compact and structured library. These technologies allow for the exploration of additive and co-operative consequences of substituting specific amino acids into multiple positions within the CDRs We will utilize Bioren's technology platform to improve the affinity of an existing anti- Botulinum neurotoxin type B (BoNT/B) antibody fragment. This higher affinity antibody fragment can be utilized to increased the sensitivity and selectivity of current detection and monitoring devices against the toxin
